Company Name | Emcure Pharmaceuticals Limited |
Open Date | 03-07-2024 |
Close Date | 05-07-2024 |
Exchange | BSE, NSE |
Lot Size | 14 Shares |
Issue Price | ₹960 to ₹1008 per share |
Issue Size | 1,93,65,346 shares |
Application Amount | ₹ 14,112 (14 shares) – 1,97,568 (196 shares) |
Recommendation | Apply |
Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files. Emcure Pharmaceuticals has 13 manufacturing facilities in India. As of September 30, 2023, the company’s marketing and distribution network in India included over 5,000 stockists, served by 37 carry-and-forward agents. As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India.
KPI’s | 2021 | 2022 | Dec-2023 |
Revenue | 5,855.39 | 5,985.81 | 6,658.25 |
EBITDA | 1,329.91 | 1,181.18 | 1,229.72 |
Net Profit | 702.56 | 561.85 | 527.58 |
RoCE | 35.02% | 25.21% | 19.96% |
ROE | 35.35% | 22.46% | 17.87% |
P/E | 27.53 | 34.26 | 36.60 |
Opening Date | 03/07/2024 |
Closing Date | 05-07-2024 |
Basis of Allotment | 08-07-2024 |
Initiation of Refunds | 09-07-2024 |
Credit of Shares to Demat | 09-07-2024 |
Listing Date | 10-07-2024 |
Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company. |
General Corporate Purposes. |
Registered Office | Emcure Pharmaceuticals Limited Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune -411 057 |
Phone | +91 20 3507 0033 |
investors@emcure.co.in | |
Website | https://www.emcure.com/ |
Emcure Pharma IPO DRHP |
Emcure Pharma IPO RHP |
Name | Link Intime India Private Ltd |
Phone | +91-22-4918 6270 |
emcure.ipo@linkintime.co.in | |
Website | https://linkintime.co.in/initial_offer/public-issues.html |
Anchor Investor Shares Offered | 5,779,850 (30.00%) |
QIB Shares Offered | 3,853,234 (20.00%) |
NII (HNI) Shares Offered | 2,889,926 (15.00%) |
Retail Shares Offered | 6,743,160 (35.00%) |
Share Holding Pre Issue (Promoters) | 83.21% |
Share Holding Post Issue (Promoters) | 78.24% |